company background image
VRDN

Viridian Therapeutics NasdaqCM:VRDN Stock Report

Last Price

US$17.22

Market Cap

US$880.3m

7D

5.6%

1Y

-37.4%

Updated

01 Dec, 2023

Data

Company Financials +

Viridian Therapeutics, Inc.

NasdaqCM:VRDN Stock Report

Mkt Cap: US$880.3m

VRDN Stock Overview

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases.

VRDN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Viridian Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Viridian Therapeutics
Historical stock prices
Current Share PriceUS$17.22
52 Week HighUS$39.00
52 Week LowUS$10.93
Beta0.93
1 Month Change36.67%
3 Month Change-9.89%
1 Year Change-37.38%
3 Year Change2.93%
5 Year Change-63.79%
Change since IPO-90.51%

Recent News & Updates

Recent updates

Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

Sep 12
Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

May 15
Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

Apr 18
Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Jan 08
Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market

Sep 09

Viridian Therapeutics board compensation committee approves inducement grants

Sep 02

An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Aug 22
An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Viridian Therapeutics Q2 2022 Earnings Preview

Aug 12

Viridian Therapeutics gets a new COO

Jun 23

Viridian Therapeutics (VRDN) Investor Presentation - Slideshow

Jun 08

Viridian Therapeutics reports Q1 results

May 06

Miragen: Viridian Therapeutics Acquisition Offers Good Speculative Entry Opportunity

Dec 08

Shareholder Returns

VRDNUS BiotechsUS Market
7D5.6%2.9%1.1%
1Y-37.4%-7.7%11.9%

Return vs Industry: VRDN underperformed the US Biotechs industry which returned -7.9% over the past year.

Return vs Market: VRDN underperformed the US Market which returned 11% over the past year.

Price Volatility

Is VRDN's price volatile compared to industry and market?
VRDN volatility
VRDN Average Weekly Movement8.6%
Biotechs Industry Average Movement11.4%
Market Average Movement6.1%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.9%

Stable Share Price: VRDN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: VRDN's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a86Steve Mahoneyhttps://www.viridiantherapeutics.com

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company’s product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-004, a discovery-stage therapeutic antibody program for rare disease; and VRDN-005 and VRDN-006, a preclinical program for autoimmune disease.

Viridian Therapeutics, Inc. Fundamentals Summary

How do Viridian Therapeutics's earnings and revenue compare to its market cap?
VRDN fundamental statistics
Market CapUS$880.29m
Earnings (TTM)-US$216.66m
Revenue (TTM)US$347.00k

2,610x

P/S Ratio

-4.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VRDN income statement (TTM)
RevenueUS$347.00k
Cost of RevenueUS$160.53m
Gross Profit-US$160.18m
Other ExpensesUS$56.48m
Earnings-US$216.66m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-4.12
Gross Margin-46,160.81%
Net Profit Margin-62,437.75%
Debt/Equity Ratio7.1%

How did VRDN perform over the long term?

See historical performance and comparison